Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
group_5_presentation_1_-_glucocorticoid_hyperfunction_cushing_s_syndrome [2017/10/02 19:12] mohamesb [Pasireotide (Signifor)] |
group_5_presentation_1_-_glucocorticoid_hyperfunction_cushing_s_syndrome [2018/01/25 15:18] (current) |
||
|---|---|---|---|
| Line 2: | Line 2: | ||
| {{youtube>J6-KRmqimIQ?medium}} | {{youtube>J6-KRmqimIQ?medium}} | ||
| + | |||
| + | ==== Adrenal Glucocorticoid Hyperfunction: Cushing's Syndrome PowerPoint ==== | ||
| + | |||
| + | {{:cushing_s_presentation.pptx|}} | ||
| ===== Introduction ===== | ===== Introduction ===== | ||
| Line 178: | Line 182: | ||
| ====Pasireotide (Signifor)==== | ====Pasireotide (Signifor)==== | ||
| - | Pasireotide acts as an analog to somatostatin, which is known as a growth hormone-inhibiting hormone. The drug inhibits adrenocorticotropin secretion from the pituitary gland, a hormone that leads to the secretion of ACTH and eventually the secretion of cortisol (McKeage, 2013). | + | Pasireotide acts as an analog to somatostatin, which is known as a growth hormone-inhibiting hormone. The drug inhibits adrenocorticotropin (ACTH) secretion from the pituitary gland, a hormone that eventually leads to the secretion of cortisol (McKeage, 2013). |
| A study done by researchers looked at patients with Cushing’s disease and prescribed them with pasireotide for 6 months. At the end of the trials, 25% of all patients have normalized UFC levels and a significant decrease in the mean UFC levels of all patients. Patients that saw a reduction in their UFC levels also saw improvements in clinical symptoms as well, such as blood pressure and body weight. The drug, however, has shown to cause hyperglycemia in patients and is still under further testing (McKeage, 2013). | A study done by researchers looked at patients with Cushing’s disease and prescribed them with pasireotide for 6 months. At the end of the trials, 25% of all patients have normalized UFC levels and a significant decrease in the mean UFC levels of all patients. Patients that saw a reduction in their UFC levels also saw improvements in clinical symptoms as well, such as blood pressure and body weight. The drug, however, has shown to cause hyperglycemia in patients and is still under further testing (McKeage, 2013). | ||
